Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05877612
Other study ID # 2023-A00638-37
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 12, 2023
Est. completion date September 2025

Study information

Verified date September 2023
Source Elsan
Contact Vincent WYART, MSc
Phone 0240958176
Email vincent.wyart@elsan.care
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this study, it is the procedure of spinal cord stimulation in Burst mode, its results and the experience of the patients that are evaluated.


Description:

There is 1 "classic" spinal cord stimulation setting that can be problematic in the case of cervical spinal cord stimulation because neck movements tend to trigger paresthesias. It is therefore possible, in a certain number of cases, that these side effects prevent the treatment from being effective. Thus, the development of new modes of spinal cord stimulation, mainly aiming at eliminating these side effects, has proven to be particularly interesting. There are 3 new modes of stimulation: high frequency stimulation which uses very short pulse durations and a stimulation frequency of the order of 1000 Hz, high density stimulation which uses long duration pulses and an intermediate stimulation frequency, and "Burst" stimulation which uses stimulation trains repeated 40 times per second. The Burst stimulation mode preferentially activates pathways in the medial part of the pain matrix, leading mainly to the cingulate cortex involved in modulating the affective, emotional and attentional side of pain. This result should theoretically be felt positively by the patient and his entourage, and the benefit should persist, or even improve with time, contrary to what is often observed with other stimulation modes. In addition, the Burst mode consumes little energy, theoretically less than conventional stimulation. It is therefore not necessary to use rechargeable stimulators, which provides greater comfort for the patient.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date September 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients between 18 and 75 years of age - Patient with CRPS of at least one upper limb - Patient affiliated to a Social Security plan - Patient who has signed and dated the no-objection form - Patient with the cognitive ability to understand the treatment and complete the questionnaires - Patient who can be followed for a minimum of 1 year Exclusion Criteria: - Patient with an uncontrolled infection - Pregnant or breastfeeding patient - Patient who has already undergone treatment by spinal cord stimulation - Patient with a contraindication to the percutaneous technique (cervical spine surgery, infection...) - Patient who cannot be followed regularly for psychological, social, family or geographical reasons - Protected participant: adult under guardianship, curatorship or other legal protection, deprived of freedom by judicial or administrative decision.

Study Design


Intervention

Device:
Implantable spinal cord stimulator
Spinal cord stimulation is possible thanks to implantable spinal cord neurostimulators. These are medical devices, which include a stimulation electrode and an implantable box, designed to deliver electrical stimulation for pain relief. The electrode is implanted in the epidural space in order to stimulate the posterior cords of the spinal cord through the dura mater, at the dorsal or cervical level.

Locations

Country Name City State
France Clinique BRETECHE Nantes

Sponsors (2)

Lead Sponsor Collaborator
Elsan Abbott

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain assessment at 3 months after implant The analgesic outcome of spinal cord stimulation will be assessed by comparing the preoperative visual analogue pain scales (VAS) (ranging from 0: "No pain" to 100: "Maximum pain imaginable") to those performed at the 3rd month visit (3 months). Patients with a VAS score of 50% or more improvement will be considered "improved". The VAS value retained corresponds to the average of 3 values taken during the day (morning, noon and evening). 3 months
Secondary procedure assesment By using:
- VAS (ranging from 0: "No pain" to 100: "Maximum pain imaginable")
1 month, 3 months, 6 months and 12 months
Secondary Assessing attention and working memory By using:
- Trail Making Test (Reitan RM 1958) (2 parts A and B measured in seconds: The maximum score for part A is 100", 101" indicating that the test was not completed. The maximum score for Part B is 300", 301" indicating that the test was not completed)
3 months and 12 months
Secondary qualitatively evaluate the effectiveness of the procedure Semi-structured interviews with patients and their families oriented towards the evaluation of attention, affectivity and emotions. 3 months
Secondary Medication use Medication quantification scale (MQS) (Harden RN 2005): ranging from 0 (no antalgic medication used) to 126 (maximum antalgic medication used) 1 month, 3 months, 6 months and 12 months
Secondary procedure assesment By using:
- Hospital Anxiety and Depression scale (HAD) (Mykletun A 2001) (2 columns ranging from 0 " no or few anxiety" to 21 "high anxiety"
1 month, 3 months, 6 months and 12 months
Secondary procedure assesment By using:
- Global Perceived Effect scale (GPE, Kamper SJ 2010) (ranging from 1 "very bad" to 7 "very good")
1 month, 3 months, 6 months and 12 months
Secondary Assessing attention and working memory By using:
- WAIS-IV (Benson N 2010) ( 4 subtests submited with 10 items in all (ranging 0 to 19 each), to calculate intelligence quotient with a minimum at 0 and a maximum at 190)
3 months and 12 months
See also
  Status Clinical Trial Phase
Completed NCT06100107 - Mirror Therapy in Complex Regional Pain Syndrome Type I N/A
Terminated NCT00006289 - Neurotropin to Treat Chronic Neuropathic Pain Phase 2
Terminated NCT03309774 - Complex Regional Pain Syndrome in Children: Impact of Bergès Relaxation on the Autonomic Balance N/A
Completed NCT00625976 - Graded Exposure (GEXP) in Vivo Versus Physiotherapy in Complex Regional Pain Syndrome Type I (CRPS-I) N/A
Not yet recruiting NCT06302920 - Effect of Kinesiotaping on Pain,Edema and Kinesiophobia in Patients With Complex Regional Pain Syndrome N/A
Recruiting NCT04703647 - Longitudinal Follow-up Study About Complex Regional Pain Syndrome (CRPS) Patients
Completed NCT03377504 - Clinical Evaluation of the Effects of Mirror Therapy in Patients With Complex Regional Pain Syndrome (CRPS) Type 1 N/A
Recruiting NCT06306157 - Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome Phase 4
Recruiting NCT05745025 - rTMS and Rehabilitation for Individuals With CRPS Type 1 N/A
Terminated NCT04667364 - Pain in Complex Regional Pain Syndrome N/A